SEC Form 4 · accession 0001681871-17-000004
Bausch Health Companies Inc. · BHC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christina Ackermann
Officer — EVP and General Counsel
Period of report
Jan 6, 2017
Accepted (ET)
Jan 10, 2017 · 7:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885590
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, no par valueF1,F2 | Jan 6, 2017 | A | 24,575 | $0.00 | A | 68,419 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF3 | — | Jan 6, 2017 | A | 16,384 | A | — | Jan 6, 2020 | Common Stock | 16,384 | 16,384 | D |
Explanation of responses
- F1Represents the award of Restricted Share Units ("RSUs") which will vest one-third on each of the three anniversaries following the date of grant, subject to the reporting person's continued service subject to continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant").
- F2The total number of shares excludes the 78,918 performance-vesting RSUs previously included in Column 5 of the reporting person's Form 4 filed on August 10, 2016, the target number of which granted to the reporting person was 26,306 and the maximum number of which that can be distributed is 78,918.
- F3Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 8,192 and the maximum number that can be distributed is 16,384. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured on January 6, 2020 (the "Measurement Date"). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award.